Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

209,745 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A two-dose optimum for recombinant S1 protein-based COVID-19 vaccination.
Hu Z, Chen JP, Xu JC, Chen ZY, Qu R, Zhang L, Yao W, Wu J, Yang H, Lowrie DB, Liu Y, Fan XY. Hu Z, et al. Among authors: liu y. Virology. 2022 Jan;566:56-59. doi: 10.1016/j.virol.2021.11.011. Epub 2021 Dec 1. Virology. 2022. PMID: 34864488 Free PMC article.
A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2.
Zhang L, Cao L, Gao XS, Zheng BY, Deng YQ, Li JX, Feng R, Bian Q, Guo XL, Wang N, Qiu HY, Wang L, Cui Z, Ye Q, Chen G, Lu KK, Chen Y, Chen YT, Pan HX, Yu J, Yao W, Zhu BL, Chen J, Liu Y, Qin CF, Wang X, Zhu FC. Zhang L, et al. Among authors: liu y. Natl Sci Rev. 2021 Mar 27;8(8):nwab053. doi: 10.1093/nsr/nwab053. eCollection 2021 Aug. Natl Sci Rev. 2021. PMID: 34676098 Free PMC article.
Safety and Immunogenicity of a Recombinant Two-Component SARS-CoV-2 Protein Vaccine: Randomized, Double-Blind, Placebo-Controlled Phase I and Phase II Studies.
Wynne C, Balgos A, Li J, Hamilton P, Tirador L, Jaen AM, Mo C, Yue Z, Ma Y, Wang Q, Wen R, Yao Z, Yu J, Yao W, Zhang J, Zheng H, Hong K, Zhu F, Liu Y. Wynne C, et al. Among authors: liu y. Infect Dis Ther. 2024 Jan;13(1):57-78. doi: 10.1007/s40121-023-00896-w. Epub 2023 Dec 16. Infect Dis Ther. 2024. PMID: 38103161 Free PMC article.
Immunogenicity and safety of boosting with a recombinant two-component SARS-CoV-2 vaccine: two randomized, parallel-controlled, phase 2 studies.
Balgos A, Hannawi S, Chen WL, Abuquta A, Safeldin L, Hassan A, Alamadi A, Tirador L, Jaen AM, Villalobos RE, Mo C, Yue ZJ, Ma Y, Wang QS, Wen RD, Yao Z, Yu JP, Yao WR, Zhang JH, Hong KX, Liu Y, Li JX. Balgos A, et al. Among authors: liu y. Expert Rev Vaccines. 2024 Jan-Dec;23(1):419-431. doi: 10.1080/14760584.2024.2334423. Epub 2024 Apr 2. Expert Rev Vaccines. 2024. PMID: 38529685 Free article. Clinical Trial.
Correction to: Safety and Immunogenicity of a Recombinant Two-Component SARS-CoV-2 Protein Vaccine: Randomized, Double-Blind, Placebo-Controlled Phase I and Phase II Studies.
Wynne C, Balgos A, Li J, Hamilton P, Tirador L, Jaen AM, Mo C, Yue Z, Ma Y, Wang Q, Wen R, Yao Z, Yu J, Yao W, Zhang J, Zheng H, Hong K, Zhu F, Liu Y. Wynne C, et al. Among authors: liu y. Infect Dis Ther. 2024 Jul;13(7):1723-1724. doi: 10.1007/s40121-024-00998-z. Infect Dis Ther. 2024. PMID: 38874695 Free PMC article. No abstract available.
209,745 results
You have reached the last available page of results. Please see the User Guide for more information.